Napredna pretraga

Pregled bibliografske jedinice broj: 335607

Potential benefit of statins and folic acid in the prevention of nephropathy


Ljubić, Spomenka; Vučić Lovrenčić, Marijana; Božikov, Jadranka; Pavlić-Renar Ivana; Metelko, Željko
Potential benefit of statins and folic acid in the prevention of nephropathy // Abstracts of the 19th World Diabetes Congress / Marshall, Sally (ur.).
Oxford, UK: Blackwell Publishing LTD., 2006. str. 96-96 (poster, međunarodna recenzija, sažetak, znanstveni)


Naslov
Potential benefit of statins and folic acid in the prevention of nephropathy

Autori
Ljubić, Spomenka ; Vučić Lovrenčić, Marijana ; Božikov, Jadranka ; Pavlić-Renar Ivana ; Metelko, Željko

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of the 19th World Diabetes Congress / Marshall, Sally - Oxford, UK : Blackwell Publishing LTD., 2006, 96-96

Skup
19th World Diabetes Congress

Mjesto i datum
Cape Town, Južna Afrika, 03-07.12.2006

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Folic Acid; Diabetic Nephropathy; Statins

Sažetak
Aims: Elevated homocysteine (HCY) level might increase the risk of diabetic nephropathy, particularly in hypertensive patients with albuminuria. The aim of the study was to investigate the association between homocysteine level, hypertension and albuminuria, as well as therapeutic possibilities associated with the above parameters in the prevention of nephropathy. Methods: A total of 266 type 2 diabetic patients (54.4 &plusmn ; 10.8 years old ; diabetes duration 12.1 &plusmn ; 7.4 years) were studied during a one-year follow-up. Patients were randomized to receive either atorvastatin (n = 59), pravastatin (n = 41), simvastatin (n = 48), folic acid (n = 44) or lisinopril (n = 35). The control group included 39 patients. HCY, atherogenic index of plasma (AIP), pulse pressure (PP) and albumin excretion rate (AER) were determined. The patients were assigned to groups based on AER (<30 mg/24 h, 30&#8211; 300 mg/24 h, >300 mg/24 h) and PP (< 45, 45&#8211; 50, 50&#8211; 65, > 65). Among-group differences were tested by one-way ANOVA and differences between the beginning and the end of the study using Wilcoxon signed ranks test. Results: ANOVA revealed significant differences in initial HCY and AIP (P = 0.001 and P = 0.041, respectively) according to AER, and in HCY and AIP (both P < 0.001) according to PP. PP and AER were significantly reduced in the lisinopril-treated group (P < 0.001) (Wilcoxon test). Both AIP and PP were significantly reduced in simvastatin- (P < 0.001 and P = 0.002, respectively) and atorvastatin&#8211; (P < 0.001 and P = 0.009, respectively) treated groups. HCY was significantly reduced in simvastatin&#8211; , pravastatin&#8211; and folic acid-treated groups (P = 0.012, P = 0.005 and P = 0.001, respectively), primarily in the group of patients with normoalbuminuria (P < 0.05). The reduction in HCY was most pronounced in the folic acid-treated group (P < 0.01). Conclusion: In addition to an effect of lisinopril on AER and PP, folic acid, reducing HCY, and statins, reducing HCY, AIP and PP, might be a support in the prevention of diabetic nephropathy.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE